UNSPSC 51386613: Hydrocortisone/urea

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE200. This VA Drug Class (DE200) classifies this compound as belonging to the group ANTI-INFLAMMATORY, TOPICAL.

UNSPSC 51386613 Hydrocortisone/urea is a Commodity code, but the recent state and local activity tagged under it does not align with the code's stated scope. The three most recent opportunities—a Seminole County naloxone and drug deactivation systems procurement, a Texas HHS direct-to-manufacturer prescription RFI, and a Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) generic pharmaceuticals RFP—involve naloxone, multi-source generic drugs, and OTC products rather than hydrocortisone/urea formulations. This mismatch suggests either inconsistent tagging in state and local procurement systems or that the code as currently indexed carries minimal relevant recent activity. The opportunities that are posted do reflect broader pharmaceutical and medical-supply sourcing across state health departments, county public health agencies, and cooperative purchasing coalitions, with vendors expected to meet cGMP certification, Drug Supply Chain Security Act compliance, E-Verify requirements, and substantial insurance coverage including commercial general liability up to $5 million per occurrence.

Recent activity spans Florida, Texas, and Minnesota through cooperative purchasing and direct health agency procurement. Seminole County, Florida issued an IFB (IFB60459723LAS) on June 30, 2026, for 1,900 units of naloxone and 800 drug deactivation systems annually with a July 26, 2023 response deadline and quarterly delivery requirements to its Community Health Building. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to explore direct-to-manufacturer prescription fulfillment models with no fixed award value disclosed. MMCAP, administered by Minnesota's Department of Administration, issued an RFP (S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 deadline, extending across Minnesota and Oregon through three authorized wholesalers with a July 1, 2026 contract start. None of the three opportunities specify explicit small-business, minority-business, or other disadvantaged-enterprise set-asides, though all require standard E-Verify and drug-free workplace certification.